Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Abdulla A. Damluji, MD, PhD Profile picture
@DrDamluji
Nov 4, 2021 • 5 tweets • 4 min read • Read on X
Scrolly
EROSION III

OCT vs angiography

Study population: STEMI

Randomized 1:1

Outcomes MACCE at 1 month and 1 year

#TCT2021
Results
Secondary endpoint and procedural data
Limitations
Conclusions

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Abdulla A. Damluji, MD, PhD Profile picture
May 13
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM

🥸 SURMOUNT-5 Trial: Wow!

😱 Summary

👇👇👇 Image
🥸 1️⃣ SURMOUNT-5 directly compares tirzepatide and semaglutide for obesity in adults without diabetes. First head-to-head randomized trial of these two GLP-1–based agents. Published @NEJM, May 2025.

[DOI: 10.1056/NEJMoa2416394]
🥸 2️⃣ 751 adults with BMI ≥30 or ≥27 + 1 comorbidity (HTN, dyslipidemia, OSA, or CVD) were randomized to tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. No participants had type 2 diabetes.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Apr 29
Healthy ageing in older adults with cardiovascular disease: @ESC_Journals

🥸 So proud of Nathalie, Jon & @KritiKalra092 for their hard work

😱 With my friend @MichaelGNanna in published in the European Heart Journal

🥸What is healthy aging? How do we achieve it?

👇👇👇 Image
🥸 1️⃣ Healthy ageing in cardiovascular disease matters because by 2050, adults 65+ will represent over 20% of the U.S. and nearly 30% of Europe's population, dramatically shifting healthcare needs.
🥸 2️⃣ Cardiovascular disease already leads all causes of death globally, and as populations age, CVD-related disability and healthcare costs will keep rising.
Read 24 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 31
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism: @NEJM

🥸 - good work #ACC25 @ACCinTouch

👇👇👇 Image
🥸1️⃣ In cancer-associated VTE, extended anticoagulation is common—but the dose remains uncertain. The API-CAT trial tested reduced-dose vs. full-dose apixaban after 6 months of initial therapy.
🥸2️⃣ 1,766 patients with active cancer and prior VTE were randomized to apixaban 2.5 mg BID or 5 mg BID for 12 months. Median follow-up was nearly 12 months.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 31
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates: @NEJM

🥸 Great work from Germany on global life time risk of CVD risk

😱 Summary

👇👇👇 Image
🥸1️⃣ Lifetime cardiovascular risk increases with the number of classic risk factors you carry at age 50. The Global Cardiovascular Risk Consortium analyzed over 2 million people to estimate how much risk factors shorten life and healthspan.
🥸2️⃣ Five risk factors were studied: high blood pressure, high cholesterol, diabetes, smoking, and unhealthy body weight.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 31
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a): @NEJM #ACC25

🥸This is a great trial

😱 Let's summarize

👇👇👇 Image
🥸1️⃣ Elevated concentrations of lipoprotein(a) are a strong, independent risk factor for cardiovascular disease. Lepodisiran, a long-acting small interfering RNA, targets hepatic production of lipoprotein(a).
🥸2️⃣ In the ALPACA trial, 320 adults with baseline lipoprotein(a) ≥175 nmol/L were randomly assigned to receive lepodisiran (16 mg, 96 mg, or 400 mg) or placebo.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 1
2025 ACC/AHA/ACEP/NAEMSP/SCAI
Guideline for the Management of Patients
With Acute Coronary Syndromes: @CircAHA @JACCJournals

🥸Here are class 1 recommendations from the document; Massive effort - congratulations to the authors: @SVRaoMD

😱 Below

👇👇👇 Image
🥸1️⃣ In patients with suspected ACS, a 12-lead ECG should be acquired and interpreted within 10 minutes of first medical contact to identify patients with STEMI.
🥸2️⃣ In patients with suspected ACS in which the initial ECG is nondiagnostic of STEMI, serial ECGs to detect potential ischemic changes should be performed, especially when clinical suspicion of ACS is high, symptoms are persistent, or the clinical condition deteriorates.
Read 37 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(